美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

三倍做多标普生物-Direxion

231.99

-11.1000-4.57%

盘后：231.72-0.2667-0.11%17:08 EDT

成交量：29.36万

成交额：6,963.03万

市值：6.20亿

市盈率：- -

高：244.67

开：241.52

低：230.22

收：243.09

52周最高：341.93

52周最低：102.35

股本：267.45万

流通股本：267.45万

量比：0.45

换手率：10.98%

股息：0.90

股息率：0.39%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

【律师讲堂】秦天说法 | “超龄用工≠随便用工”，速看，超龄劳动者权益保障新规怎么说！

Prime Medicine（PRME）盘前涨10.45% FDA批准其PM647的新药临床试验申请

夏邑人速看!延续实施扩大社会保险补贴范围政策，直补个人，最长可领12个月!

兰州市自明年起不再向用人单位收取退休人员大额医疗保险费

中国兰州网

美国 FDA 批准一款肾病药物后，默沙东股价持平但成交量激增，最新上涨 0.50%，报 148.81 美元。

医疗保健行业综述：市场观察

特朗普提名的美国食品药品监督管理局候任人奥弗顿就米非司酮表态：根据FDA的审评结果，该药物符合安全性与有效性标准。

特朗普提名的FDA局长人选奥弗顿：产品个案审查应依法并参考FDA职业官员建议进行。

遭FDA进口禁令，圣诺生物美国业务亮起红灯

医疗保健行业综述：市场观察

全球多癌早筛闯过FDA专家这一关，华大基因早筛业务迎来下一轮产品兑现窗口

晶泰向美国FDA提交KQTD-126新药临床试验申请

医疗板块市场综述：行业快讯集锦

FDA未发警告信先下禁令，圣诺生物对美业务“急刹车”

医疗保健板块市场动态综述

医疗保健板块市场快讯汇总

医疗保健板块市场快讯综述

健友股份：子公司获美国FDA硫酸阿米卡星注射液生产场地批件

健友股份：子公司获美国FDA硫酸阿米卡星注射液生产场地批件

圣诺生物：子公司被FDA纳入66-40名单或对业绩产生一定不利影响

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/LABU/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":231.99,"timestamp":1791835200000,"preClose":243.09,"halted":0,"volume":293575,"hourTrading":{"tag":"盘后","latestPrice":231.7233,"preClose":231.99,"latestTime":"17:08 EDT","volume":695,"amount":161048.5692,"timestamp":1791839328329,"change":-0.2667,"changeRate":-0.00115,"amplitude":0.004785},"delay":0,"changeRate":-0.04566210045662098,"floatShares":2674486,"shares":2674486,"eps":0,"marketStatus":"盘后交易","change":-11.1,"latestTime":"10-12 17:12:05 EDT","open":241.52,"high":244.6716,"low":230.2215,"amount":69630300.5165,"amplitude":0.059443,"askPrice":235.5,"askSize":200,"bidPrice":230.4,"bidSize":200,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791849600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":243.09,"sharesOutstanding":3074486,"nav":242.822,"aum":649423578.22,"dividendRate":0.003877,"bidAskSpread":0.002692,"preHourTrading":{"tag":"盘前","latestPrice":242.43,"preClose":243.09,"latestTime":"09:29 EDT","volume":24862,"amount":6085203.2304,"timestamp":1791811795117,"change":-0.66,"changeRate":-0.002715,"amplitude":0.021844},"postHourTrading":{"tag":"盘后","latestPrice":231.7233,"preClose":231.99,"latestTime":"17:08 EDT","volume":695,"amount":161048.5692,"timestamp":1791839328329,"change":-0.2667,"changeRate":-0.00115,"amplitude":0.004785},"volumeRatio":0.450251,"impliedVol":0.9772,"impliedVolPercentile":0.7331},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2674486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.450251,"shares":2674486,"dividePrice":0.8994,"high":244.6716,"amplitude":0.059443,"preClose":243.09,"low":230.2215,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":231.99,"eps":0,"divideRate":0.003877,"volume":293575,"delay":0,"ttmEps":0,"open":241.52,"prevYearClose":159.39,"prevWeekClose":243.09,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":257.38,"twentyDayClose":268.39,"sixtyDayClose":265.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670475113","title":"【律师讲堂】秦天说法 | “超龄用工≠随便用工”，速看，超龄劳动者权益保障新规怎么说！","url":"https://stock-news.laohu8.com/highlight/detail?id=2670475113","media":"天津东丽","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670475113?lang=zh_cn&edition=fundamental","pubTime":"2026-09-26 14:30","pubTimestamp":1790404200,"startTime":"0","endTime":"0","summary":"用人单位应当保障超龄劳动者获得劳动报酬、休息休假、劳动安全卫生、工伤保障等基本权益。双方约定的终止条件出现或者双方协商一致解除用工协议的，用工终止。超龄劳动者因工作原因受到事故伤害或者患职业病的，按照规定进行工伤认定、劳动能力鉴定并享受相应的工伤保障待遇。超龄劳动者工伤保障办法另行制定。第二十二条工会依法维护超龄劳动者的合法权益，对用人单位保障超龄劳动者的合法权益情况进行监督。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-26/doc-initcuta8573876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","BK4585","XLV","BK4581","XBI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670441624","title":"Prime Medicine（PRME）盘前涨10.45% FDA批准其PM647的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2670441624","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670441624?lang=zh_cn&edition=fundamental","pubTime":"2026-09-25 17:33","pubTimestamp":1790328824,"startTime":"0","endTime":"0","summary":"金吾财讯 | Prime Medicine（PRME）盘前涨10.45%，报3.391美元。消息面上，美国食品药品监督管理局（FDA）批准其PM647的新药临床试验申请（IND）。获批使Prime Medicine能够启动一项评估PM647用于患有该遗传性疾病成人患者的1/2期试验。预计将于2027年获得初步临床数据。PM647是一种用于治疗α-1抗胰蛋白酶缺乏症的实验性基因编辑疗法。PM647旨在修复导致α-1抗胰蛋白酶缺乏症的基因突变。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306480","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BMED","PSYK","PRME","LABU","IBBQ","BK4139","MDTX","BK4585","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670178448","title":"夏邑人速看!延续实施扩大社会保险补贴范围政策，直补个人，最长可领12个月!","url":"https://stock-news.laohu8.com/highlight/detail?id=2670178448","media":"掌握夏邑","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670178448?lang=zh_cn&edition=fundamental","pubTime":"2026-09-25 13:48","pubTimestamp":1790315280,"startTime":"0","endTime":"0","summary":"4.无合同年限限制:本次政策不强制要求一年以上劳动合同。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-25/doc-iniszmnc4546647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","BK4581","BK4585","BK4588","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670941456","title":"兰州市自明年起不再向用人单位收取退休人员大额医疗保险费","url":"https://stock-news.laohu8.com/highlight/detail?id=2670941456","media":"中国兰州网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670941456?lang=zh_cn&edition=fundamental","pubTime":"2026-09-25 09:41","pubTimestamp":1790300460,"startTime":"0","endTime":"0","summary":"记者9月24日从兰州市医保局获悉，自2027年1月1日起，全市企业退休人员大额医疗保险费单位缴费部分不再收取，个人缴费费率及缴费方式不变；灵活就业退休人员大额医疗保险个人缴费费率减半。用人单位特别是小微企业，不再缴纳退休人员大额医疗保险费，减轻用工成本，持续优化营商环境。灵活就业退休人员大额医疗保险个人缴费费率由0.5%调整为0.25%，全年人均减轻缴费负担226.32元，有效减轻参保群众经济负担。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-25/doc-inisyywi4652149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","XLV","LABU","BK4588","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670901764","title":"美国 FDA 批准一款肾病药物后，默沙东股价持平但成交量激增，最新上涨 0.50%，报 148.81 美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2670901764","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670901764?lang=zh_cn&edition=fundamental","pubTime":"2026-09-25 03:29","pubTimestamp":1790278155,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["UUP","BK4585","BK4588","LABU","UDN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136752222","title":"医疗保健行业综述：市场观察","url":"https://stock-news.laohu8.com/highlight/detail?id=1136752222","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136752222?lang=zh_cn&edition=fundamental","pubTime":"2026-09-25 00:27","pubTimestamp":1790267220,"startTime":"0","endTime":"0","summary":"医疗保健板块最新市场观察汇总。分析师在一份研究报告中称，UCB高管在美国银行的一场活动上显得很有信心，认为公司最畅销产品Bimzelx能够抵御新药的竞争。联昌国际证券分析师Chun Sung Oong在一份报告中表示，马来西亚医疗保健板块可能继续受到非传染性疾病患病率上升、人口老龄化和健康意识增强的支撑。由于公立医院入住率高企，患者转向私立医院，IHH的业务预计将从中受益。联昌国际维持对马来西亚医疗保健板块的增持评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","LU0234570918.USD","LU1880398471.USD","LU0130518102.USD","LU1496350502.SGD","IE0034235188.USD","LU1201861249.SGD","LU1668664300.SGD","LU1363072403.SGD","LU2265009873.SGD","LU0130517989.USD","LU0787776722.HKD","LU2129689431.USD","LU0320765646.SGD","LU1074936037.SGD","IYF","IE00BFXG1179.USD","IE00BKVL7J92.USD","LU1280957306.USD","LU0106831901.USD","LU1894683348.USD","LU0170899867.USD","LU1035773651.USD","TCAF","LU0211331839.USD","LU1894683264.USD","LU0648001328.SGD","LU0098860793.USD","XBI","LU0314106906.USD","KBWB","LU0868494617.USD","IE00BLSP4239.USD","LU2129689514.USD","IE00B1BXHZ80.USD","LU1804176565.USD","LU1366192091.USD","LU0256863811.USD","UYG","LU1201861165.SGD","LU1718418525.SGD","LU2133065610.SGD","LU0683600562.USD","XLF","LU0070302665.USD","LU1883839398.USD","IE00BLSP4452.SGD","LU0149725797.USD","LU1069347547.HKD","LU2596442595.SGD","IE00B19Z3581.USD","TFNS","IE0001KFT4U8.USD","LU0256863902.USD","LU0310800965.SGD","LU1496350171.SGD","BK4504","BK4585","IE00BZ1G4Q59.USD","LU0128525689.USD","VFH","LU0971096721.USD","BK4588","LU0203345920.USD","LU0306807586.USD","LU0980610538.SGD","LU1791807156.HKD","IE0002270589.USD","LU0417517546.SGD","LU0053666078.USD","LU0130103400.USD","IYG","FNCL","LU0320765489.SGD","LU1267930227.SGD","LU0306806265.USD","LU0321505868.SGD","XLV","IE00BBT3K403.USD","LU0234572021.USD","LU1506573853.SGD","LU0130102774.USD","BK4534","BK4207","LU0052756011.USD","LU0477156797.USD","BK4559","BK4581","IE00B19Z3B42.SGD","BK4553","LU0640476718.USD","LU0208291251.USD","LABU","FTXO","LU2129689605.HKD","LU1291159041.SGD","BAC","LU0648000940.SGD","LU1989771016.USD","LU1162221912.USD","LU0203347892.USD","LU1880398554.USD","LU0477156953.USD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669436491","title":"特朗普提名的美国食品药品监督管理局候任人奥弗顿就米非司酮表态：根据FDA的审评结果，该药物符合安全性与有效性标准。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669436491","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669436491?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 23:15","pubTimestamp":1790262929,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669547491","title":"特朗普提名的FDA局长人选奥弗顿：产品个案审查应依法并参考FDA职业官员建议进行。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669547491","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669547491?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 23:02","pubTimestamp":1790262141,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669946360","title":"遭FDA进口禁令，圣诺生物美国业务亮起红灯","url":"https://stock-news.laohu8.com/highlight/detail?id=2669946360","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669946360?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 16:37","pubTimestamp":1790239020,"startTime":"0","endTime":"0","summary":"多肽CDMO企业圣诺生物子公司圣诺制药接受FDA现场检查之后，收到483观察表，随后被列入进口禁令名单。随后企业被纳入FDA进口禁令名单，产品出口美国将受到限制。截至目前公司尚未收到FDA警告信以及最终官方处置结论，但禁令已经客观形成约束。FDA的现场检查结果直接决定企业能否拿到海外订单。后续有两大看点，一是企业整改的进度，能否尽快消除FDA提出的各项缺陷、解除进口限制；二是海外客户信心是否发生动摇，会不会出现订单流失。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-24/doc-inisxnuv5179837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK0239","BK4585","688117","LABU"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1166923246","title":"医疗保健行业综述：市场观察","url":"https://stock-news.laohu8.com/highlight/detail?id=1166923246","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166923246?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 16:29","pubTimestamp":1790238549,"startTime":"0","endTime":"0","summary":"医疗保健板块最新市场观察。0721 GMT——Hikma Pharmaceuticals新任首席财务官是“高水准人选”，RBC Capital Markets的Harry Sephton表示。这家伦敦上市的制药公司周四任命ViiV Healthcare的Rebecca Hall为下一任首席财务官。RBC称，Hall在ViiV和GSK积累的运营及财务经验应能很好地迁移至Hikma。该分析师预计Hikma将实现有序过渡，临时首席财务官Areb Kurdi将留任至Hall明年上任。由于公立医院入住率居高不下，患者转向私立医院，IHH的业务预计将从中受益。CIMB维持对马来西亚医疗保健板块的增持评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","XBI","BK4588","LABU","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669457112","title":"全球多癌早筛闯过FDA专家这一关，华大基因早筛业务迎来下一轮产品兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2669457112","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669457112?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 15:16","pubTimestamp":1790234160,"startTime":"0","endTime":"0","summary":"三项表决整体指向建议批准Galleri用于 50 岁及以上人群的多癌筛查。这次投票的意义在于，它是外界观察FDA对多癌筛查这一类产品持何审评尺度的窗口，尺度松紧会直接影响后续所有同类产品的申报预期。同期净亏损1.102亿美元，调整后EBITDA为负9030万美元；截至6月30日，现金及短期有价证券合计8.616亿美元。FDA未上诉，并于2025年","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-24/doc-inisxhpc4995817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0221","300676","LABU","BK4588","BK0196","BK0197","BK0042","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669437927","title":"晶泰向美国FDA提交KQTD-126新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437927","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669437927?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 08:38","pubTimestamp":1790210290,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","LABU","BK4585","BMED","MDTX","PSYK","BK4588","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177158344","title":"医疗板块市场综述：行业快讯集锦","url":"https://stock-news.laohu8.com/highlight/detail?id=1177158344","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177158344?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 00:22","pubTimestamp":1790180558,"startTime":"0","endTime":"0","summary":"最新一期的医疗板块市场快讯已发布，涵盖多项关键动态，仅在道琼斯通讯社于美东时间4:20、12:20及16:50独家呈现。罗氏股价上涨0.8%。下午10:46——肯纳格投资银行分析师Raymond Choo Ping Khoon在一份报告中指出，IHH医疗保健年初至今股价累计下跌10%，这可能为投资者提供了一个潜在的入场时机，因为该公司在关键市场的业务运营预计将有所改善。在印度，Gleneagles医疗的利润率有望向Fortis Healthcare看齐；同时，若大中华区业务亏损收窄速度快于预期，或能带来更多上行空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LABU","XLV","BK4581","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669092201","title":"FDA未发警告信先下禁令，圣诺生物对美业务“急刹车”","url":"https://stock-news.laohu8.com/highlight/detail?id=2669092201","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669092201?lang=zh_cn&edition=fundamental","pubTime":"2026-09-23 16:41","pubTimestamp":1790152873,"startTime":"0","endTime":"0","summary":"有业内人士指出，这意味着FDA检查人员认为该工厂在药品生产质量管理的多个核心环节存在系统性问题，而非孤立的操作失误。圣诺生物已经启动了整改程序。公司公告援引FDA官网查询，圣诺制药于2026年9月19日被正式列入第66-40号进口禁令名单。更值得注意的是，进口禁令的发布并不以警告信或OAI结论为前置条件。面对禁令，圣诺生物在公告中作出了明确承诺：在解除FDA相关警示前，全面停止所有多肽原料药对美国市场的销售与发运。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1790152812280888809","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","688117","LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163794674","title":"医疗保健板块市场动态综述","url":"https://stock-news.laohu8.com/highlight/detail?id=1163794674","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163794674?lang=zh_cn&edition=fundamental","pubTime":"2026-09-23 16:24","pubTimestamp":1790151852,"startTime":"0","endTime":"0","summary":"涵盖医疗保健领域的市场快讯，仅通过道琼斯通讯社于美东时间4:20、12:20和16:50独家发布。0246 GMT——肯纳格投行分析师Raymond Choo Ping Khoon指出，IHH医疗保健股价年初至今已回落10%，这或许正为投资者敞开一扇潜在的低吸窗口，预期其在关键市场的运营表现将逐步改善。0909 GMT——贝伦贝格分析师认为，诺和诺德在投资者日过后股价8%的跌幅实属过度反应，但这也恰恰印证了市场对2027年的担忧情绪犹存——既担心预期中的价格压力，又对CagriSema药物的上市前景持怀疑态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","BK4588","LABU","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150507917","title":"医疗保健板块市场快讯汇总","url":"https://stock-news.laohu8.com/highlight/detail?id=1150507917","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150507917?lang=zh_cn&edition=fundamental","pubTime":"2026-09-23 04:53","pubTimestamp":1790110396,"startTime":"0","endTime":"0","summary":"美东时间0638——诺和诺德在资本市场日活动上公布的多元化战略及模糊的中期销售目标，令投资者颇感失望，AlphaValue分析师Abhishek Raval如此写道。\"面对对单一分子的过度依赖，激进而大规模的业务多元化押注，加上无可挑剔的商业执行力，已是当务之急。\"然而，市场对此心存疑虑，Raval表示。AlphaValue对该丹麦药企股票给予买入评级，目标价450丹麦克朗。股价微跌0.2%，报259.40克朗。这家法意合资的眼镜集团近期因市场担心该领域将涌入新竞争者而承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LABU","XLV","BK4581","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113321759","title":"医疗保健板块市场快讯综述","url":"https://stock-news.laohu8.com/highlight/detail?id=1113321759","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113321759?lang=zh_cn&edition=fundamental","pubTime":"2026-09-23 00:23","pubTimestamp":1790094199,"startTime":"0","endTime":"0","summary":"0638 GMT - 诺和诺德的资本市场日活动公布了一系列消息，其中包括业务多元化计划及一个略显模糊的中期销售目标。然而，AlphaValue分析师阿布希谢克·拉瓦尔指出，这些内容并未令投资者感到满意。不过，市场对此仍心存疑虑。AlphaValue给予这家丹麦制药商的股票“买入”评级，目标价为450丹麦克朗。该股现跌0.2%，报259.40克朗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4588","BK4585","XBI","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669711242","title":"健友股份：子公司获美国FDA硫酸阿米卡星注射液生产场地批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2669711242","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669711242?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 16:17","pubTimestamp":1790065020,"startTime":"0","endTime":"0","summary":"9月22日，健友股份(603707.SH)公告称，公司子公司Meitheal Pharmaceuticals Inc.近日收到美国FDA签发的硫酸阿米卡星注射液(500mg/2mL、1g/4mL)增加生产场地的批件，批准在南京健友生化制 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260922/c680169738.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260922/c680169738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0186","LABU","BK0239","BK4585","BK4588","BK0046","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669112900","title":"健友股份：子公司获美国FDA硫酸阿米卡星注射液生产场地批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2669112900","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669112900?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 16:12","pubTimestamp":1790064745,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669113982","title":"圣诺生物：子公司被FDA纳入66-40名单 或对业绩产生一定不利影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2669113982","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669113982?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 12:42","pubTimestamp":1790052135,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}